Bank of New York Mellon’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.82M Buy
118,597
+7,596
+7% +$609K ﹤0.01% 2040
2026
Q1
$8.54M Sell
111,001
-1,643
-1% -$128K ﹤0.01% 2018
2025
Q4
$8.89M Sell
112,644
-3,628
-3% -$314K ﹤0.01% 1990
2025
Q3
$10.7M Sell
116,272
-2,522
-2% -$206K ﹤0.01% 1893
2025
Q2
$7.75M Sell
118,794
-468
-0.4% -$30.5K ﹤0.01% 2033
2025
Q1
$7.98M Sell
119,262
-4,570
-4% -$273K ﹤0.01% 1972
2024
Q4
$6.85M Buy
123,832
+4,404
+4% +$253K ﹤0.01% 2130
2024
Q3
$7.13M Sell
119,428
-11,728
-9% -$715K ﹤0.01% 2108
2024
Q2
$8.35M Buy
131,156
+12,865
+11% +$835K ﹤0.01% 2055
2024
Q1
$8.18M Sell
118,291
-7,860
-6% -$474K ﹤0.01% 2061
2023
Q4
$6.96M Buy
126,151
+2,434
+2% +$134K ﹤0.01% 2202
2023
Q3
$7.18M Buy
123,717
+10,234
+9% +$591K ﹤0.01% 2137
2023
Q2
$6.11M Buy
113,483
+3,994
+4% +$177K ﹤0.01% 2213
2023
Q1
$4.35M Sell
109,489
-4,608
-4% -$194K ﹤0.01% 2383
2022
Q4
$4.59M Sell
114,097
-6,537
-5% -$246K ﹤0.01% 2387
2022
Q3
$3.88M Sell
120,634
-550
-0.5% -$18.8K ﹤0.01% 2436
2022
Q2
$3.6M Sell
121,184
-1,902
-2% -$54.9K ﹤0.01% 2494
2022
Q1
$3.46M Sell
123,086
-18,293
-13% -$682K ﹤0.01% 2624
2021
Q4
$6.51M Buy
141,379
+45,477
+47% +$1.95M ﹤0.01% 2327
2021
Q3
$3.15M Buy
95,902
+2,052
+2% +$63.8K ﹤0.01% 2743
2021
Q2
$3.29M Sell
93,850
-7,029
-7% -$239K ﹤0.01% 2696
2021
Q1
$3.65M Sell
100,879
-2,857
-3% -$89.5K ﹤0.01% 2602
2020
Q4
$3.01M Sell
103,736
-5,425
-5% -$155K ﹤0.01% 2608
2020
Q3
$3.08M Buy
109,161
+3,642
+3% +$108K ﹤0.01% 2445
2020
Q2
$3.41M Buy
105,519
+850
+0.8% +$30.5K ﹤0.01% 2403
2020
Q1
$4.26M Sell
104,669
-3,940
-4% -$210K ﹤0.01% 2153
2019
Q4
$6.7M Sell
108,609
-325
-0.3% -$21.5K ﹤0.01% 2185
2019
Q3
$7.94M Sell
108,934
-329
-0.3% -$24.6K ﹤0.01% 2050
2019
Q2
$8.98M Buy
109,263
+4,442
+4% +$316K ﹤0.01% 2016
2019
Q1
$7.39M Sell
104,821
-29,768
-22% -$1.75M ﹤0.01% 2130
2018
Q4
$6.06M Buy
134,589
+474
+0.4% +$24.8K ﹤0.01% 2183
2018
Q3
$7.58M Sell
134,115
-1,442
-1% -$88.2K ﹤0.01% 2185
2018
Q2
$9.06M Buy
135,557
+6,262
+5% +$391K ﹤0.01% 2069
2018
Q1
$7.53M Sell
129,295
-62,147
-32% -$3.94M ﹤0.01% 2139
2017
Q4
$12.3M Buy
191,442
+34,577
+22% +$2.15M ﹤0.01% 1890
2017
Q3
$8.23M Buy
156,865
+30,632
+24% +$1.46M ﹤0.01% 2080
2017
Q2
$5.91M Sell
126,233
-16,281
-11% -$785K ﹤0.01% 2252
2017
Q1
$7.06M Sell
142,514
-20,840
-13% -$1.17M ﹤0.01% 2155
2016
Q4
$9.9M Sell
163,354
-30,181
-16% -$1.85M ﹤0.01% 1967
2016
Q3
$12.8M Buy
193,535
+73,728
+62% +$4.61M ﹤0.01% 1736
2016
Q2
$6.69M Sell
119,807
-5,416
-4% -$263K ﹤0.01% 2057
2016
Q1
$4.22M Buy
125,223
+8,730
+7% +$296K ﹤0.01% 2262
2015
Q4
$5.26M Buy
116,493
+12,440
+12% +$535K ﹤0.01% 2184
2015
Q3
$4.11M Buy
104,053
+23,081
+29% +$1.31M ﹤0.01% 2346
2015
Q2
$5.02M Buy
80,972
+12,512
+18% +$745K ﹤0.01% 2354
2015
Q1
$4.28M Buy
68,460
+23,120
+51% +$1.41M ﹤0.01% 2394
2014
Q4
$2.56M Buy
45,340
+14,848
+49% +$655K ﹤0.01% 2696
2014
Q3
$863K Buy
30,492
+3,003
+11% +$90K ﹤0.01% 3377
2014
Q2
$946K Buy
+27,489
New +$862K ﹤0.01% 3344

Other funds holding ANIP

Bank of New York Mellon's ANIP Position: Q2 2026 in Review

Bank of New York Mellon increased its ANI Pharmaceuticals (ANIP) stake by 6.8% in Q2 2026, buying an estimated $609K and bringing the position to 118,597 shares worth $9.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

Bank of New York Mellon first reported a position in ANIP in Q2 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2016. 172 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Bank of New York Mellon held 118,597 shares of ANI Pharmaceuticals worth $9.82M as of Q2 2026.
  • Bank of New York Mellon bought 7,596 ANI Pharmaceuticals shares in Q2 2026, an estimated $609K.
  • ANI Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2040 holding.
  • Bank of New York Mellon first reported a position in ANI Pharmaceuticals in Q2 2014 and has held it in 49 quarters since.
  • Bank of New York Mellon's ANI Pharmaceuticals position peaked at $12.8M in Q3 2016.
  • 172 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.